Thales Wins Google Cloud Technology Partner of the Year Security – Data Protection Award
Thales has been selected as the Google Cloud Technology Partner of the Year in the Security – Data Protection category. Thales was selected alongside a global field of top Google Cloud partners for excellence in developing and implementing customer solutions based on Google Cloud’s technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230829348216/en/
©Thales
The Thales and Google Cloud collaboration addresses the needs of organizations around the world that are facing ever-increasing security, sovereignty, and performance requirements for their cloud deployments. With many years of cybersecurity expertise, Thales provides the level of trust and security required for customers around the world to move to the cloud, while maintaining the necessary level of control. By combining Thales’ platform expertise with Google Cloud’s enterprise-grade solutions and cutting-edge infrastructure, the two companies work closely on a number of broad data security initiatives.
Thales, in its constant search of excellence in its security portfolio, recently announced a new collaboration to develop data security capabilities and bring additional AI-powered features to users of its CipherTrust Data Security platform. This is powered by Google Cloud’s Vertex AI machine learning capabilities, to discover, classify and protect sensitive data in the cloud. The machine learning functionality helps to automate fundamental tasks for customers and ensure their sensitive cloud-hosted data remains protected.
Since late 2022, Thales’ CipherTrust Cloud Key Manager has also supported Bring Your Own Key (BYOK) initiatives, including those for Google Cloud and Google Workspace. Thales and Google Cloud have also collaborated to operate a sovereign cloud joint venture (S3NS) for Google Cloud customers in France who seek to meet stringent data sovereignty requirements, such as those applicable to state and critical infrastructure organizations.
Thales has built a structured cloud offering for companies that want to meet the most demanding data protection standards. In France, S3NS, the joint venture between Thales and Google Cloud, aims to offer French companies and public institutions a solution providing the equivalent of Google Cloud , compliant with the “SecNumCloud” label, a certification from the French information systems security agency (ANSSI). To date, SecNumCloud has the highest level of protection in France, excluding the protection of national defense secrets, and in Europe. S3NS has a first offering already available that offers additional guarantees & controls, such as data location in Europe and external encryption managed by S3NS (based on Thales technology).
“Google Cloud’s partner awards recognize the significant impact and customer success that our partners have driven over the past year," said Kevin Ichhpurani, Corporate Vice President, Global Ecosystem and Channels at Google Cloud. "We're delighted to recognize Thales as a 2023 Google Cloud Partner Award winner, and look forward to a continued strong partnership in support of our mutual customers."
Sebastien Cano, Senior Vice President of Cloud Protection and Licensing activities at Thales, commented: “We are very proud of our ongoing relationship with Google Cloud and this latest award recognises the brilliant work we’ve been doing with them across a range of projects. Together we are helping customers around the world discover, classify and protect their data more efficiently, and ensure their move to the cloud is as secure and compliant as possible.”
Thales is also participating at Google Cloud Next, which is taking place from 29-31 August 2023. Some of the sessions include:
- Keys to the Kingdom: Everything you need to know about your encryption keys with Todd Moore, VP Encryption Products at Thales
- Cybersecurity Innovations from leading ISVs with Google Gen AI with Ashvin Kamaraju, VP Data Protection Engineering at Thales
How global leaders are addressing digital sovereignty requirements, with Cyprien Falque, CEO of S3NS More details about the event, which will be available to watch both live and on-demand online, can be found here.
|
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
|
PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230829348216/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom